cyrilzakka/clinical-trials huggingface dataset:
Post - Activation Potentiation After Plyometric and Heavy Resistance Exercise in Soccer Players

The main purpose of this study will be comparison of acute effects of plyometric and heavy resistance exercise on post-activation potentiation

This is a single-center, randomized, crossover study. Collegiate soccer players will be enrolled in this study. The study will be performed in 3 separate sessions.In the first session, participants will be familiarized with the experimental conditions and 1RM will be calculated. Participants will then be randomized to receive either heavy resistance or plyometric exercise first in the second session and then will be crossed over to receive the opposite intervention in the third session. The objective of the study is to compare the acute effects of plyometric and heavy resistance exercise on post - activation potentiation by measuring physical performance and blood lactate level.

Eligibility Criteria:
Inclusion Criteria:

* Collegiate soccer players aged 18 - 26 years
* Participants must have at least 2 years of playing experience
* Participants should be involved in sport-specific training on at least 2 occasions per week and play competitively once per week

Exclusion Criteria:

* Lower extremity reconstructive surgery in last 24 months or unresolved musculoskeletal disorder which would prohibit subject to participate in the sport.
* Participants who are consuming (or had consumed) growth hormone, anabolic steroids or any kind of performance enhancing drugs.
Effect of Midazolam on White-coat Hypertensive Dental Patients

Intravenous sedation was used for dealing with transient hypertension, so-called white-coat hypertension, before dental treatment. Midazolam used as a sedative also has antianxiety effect, and the mechanism is guessed that it minimizes patients' stress, resulting in the stability of blood pressure. The purpose of this randomized controlled trial (RCT) is to evaluate the effect of low dose of midazolam on blood pressure and anxiety scale in white-coat hypertensive dental patients.


Eligibility Criteria:
Inclusion Criteria:

SBP\>=140mmHg or DBP\>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes among dental outpatients scheduling intravenous sedation with American Society of Anesthesiologists physical status I or II.

Exclusion Criteria:

1. Uncontrolled or unstable hypertension
2. Secondary hypertension such as hyperthyroidism and pheochromocytoma
3. Taking sympathomimetic drugs
4. Contraindication of midazolam such as myasthenia gravis and acute narrow-angle glaucoma
5. A pregnant woman or during lactation period
6. Psychiatric disorder such as schizophrenia
7. Not having intelligence enough to read, understand and write a Japanese version of STAI
8. Judged unsuitable by a researcher
The Extension of HAPO Follow-up Study

The prevalence of diabetes mellitus (DM) and cardiovascular disease (CVD) escalate remarkably worldwide and obesity becomes an epidemic disease. This study is interested in how the model of Developmental Origin of Health and Disease (DOHaD) influence individual's health status as they reach young adulthood. Since the mothers from HAPO study have not been subjected to antenatal treatment on the various degree of maternal hyperglycaemia in pregnancy, this would be an unique cohort that allows determination of the effect of various degree of maternal hyperglycaemia below the level of overt DM, on children's cardiometabolic risk in Chinese population.

The investigators recruited 1760 Chinese pregnant women between 2000 and 2005. The HAPO study investigated whether any adverse outcome was associated with mild degree of GDM. All mothers underwent a 75-gram OGTT at 24-32 weeks gestation, but clinicians were blinded to the results as long as the fasting PG was ≤ 5.8 mmol/L \& 2-hour PG ≤ 11.1 mmol/L. The maternal serum C-peptide and HbA1c, cord serum C-peptide and early neonatal PG, pregnancy outcome and the neonatal anthropometric parameters are available for future study. This is so far the largest cohort in a Chinese population who has been investigated for glycaemia during pregnancy, but with OGTT results remained undisclosed to subjects and clinicians. This unique cohort can allow us to study the effect of in-utero hyperglycemia on the cardiometabolic risks at childhood, adolescence and adulthood.

Eligible subjects are all mother-child pairs participating in the original HAPO study. Children born preterm before 37 weeks of gestation, non-Chinese and whose mother's OGTT result were unblinded during pregnancy will be excluded.The family (the child and the mother) will be invited for a third follow-up assessment.

Eligibility Criteria:
Inclusion Criteria:

* Mother-child pairs who had been assessed in HAPO follow-up study at either 7 years or 11-14 years old

Exclusion Criteria:

* Children born preterm before 37 weeks of gestation
* Non-Chinese
* Mothers' OGTT results were unblinded during pregnancy
Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer

A prospective, open, one-arm clinical study to evaluate the efficacy and safety of jinyouli in the first-line treatment of advanced pancreatic cancer with albumin paclitaxel combined with S-1.Chemotherapy regimen: (1) chemotherapy: albumin paclitaxel, 120mg / m2, intravenous infusion for 30 minutes, D1. S-1, taken orally after meal, D1 - 14. (2) patients who met the input / discharge criteria were given jinyouli injections 24 hours after the end of intravenous infusion of albumin paclitaxel during the treatment period.


Eligibility Criteria:
Inclusion Criteria:

* (1) Age ≥ 18 years, ≤70 years;
* (2) Patients with Advanced Pancreatic Cancer diagnosed by histopathology，the expected survival time is more than 3 months;
* (3) Neutropenia of ≥2 degree occurred with the albumin paclitaxel + S-1 regimen in the previous cycle.
* (4) KPS score≥70points;
* (5) The peripheral blood routine of the patients was normal: ANC ≥ 2.0x109 / L, platelet count ≥ 90 × 109 / L, HB ≥ 80g / L before enrollment, and there was no bleeding tendency;
* (6) Patients volunteered to participate in the trial and signed a written informed consent to be followed up.

Exclusion Criteria:

* (1) There are currently hard-to-control infections or systemic antibiotic treatment within 72 h of chemotherapy；
* (2) Any abnormal bone marrow hyperplasia and other abnormal hematopoietic function；
* (3) Patients who had received bone marrow or hematopoietic stem cell transplantation within the previous 3 months；
* (4) Previous patients with other malignant tumors not cured, or brain metastases；
* (5) Liver function tests total bilirubin (TBIL), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) are \>2.5 times the upper limit of normal, if the above indicators are \>5 times due to liver metastasis Upper limit of normal value;
* (6) Renal function test: serum creatinine (Cr) exceeded the upper limit of normal value；
* (7) Allergic to this product or other biological products derived from genetically engineered escherichia coli；
* (8) Suffering from a mental or nervous system disorder, lacking self-awareness or coordination；
* (9) Patients who are expected to have a short survival and have difficulty tolerating chemotherapy；
* (10) Pregnant and nursing female patients；
* (11) People who are using other drugs of the same category or are in clinical trials of other drugs；
* (12) The investigator judges patients who are not suitable for participation.
Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures

A prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine given by local injection at all the wound sites in patients undergoing urologic surgeries.

A prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine given by local injection at all the wound sites in patients undergoing urologic surgeries. Subjects of prospective study will be randomly divided using electronic program into two groups:

The first group will receive intraoperative local Liposomal Bupivacaine injection at the port placement site. The control group will receive will local Marcaine (bupivacaine HCl) injection

Primary Outcome Measures:

* Total opioid consumption measured in intravenous morphine equivalents dose during the postoperative hospital Stay
* Postoperative pain assessment using visual Analog Pain Scores \& Brief Pain Inventory form.
* Length of Hospital Stay
* Time to First Opioid Use.
* Postoperative Constipation , paralytic ileus

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing urologic surgery.

Exclusion Criteria:

* Pregnant and/or nursing mothers.
* Allergy to bupivacaine.
* History of drug/alcohol abuse.
* Severe cardiovascular, hepatic, renal disease or neurological impairment.
Effect of Off-site Assistance on Success Rate of Selective Cannulation During hands-on ERCP Training

Endoscopic retrograde cholangiopancreatography (ERCP) is a technically challenging procedure. It takes time to learn the basic skills and need at least 180 - 200 cases for trainees to achieve competency in ERCP. Hands-on practice in patients remains the gold standard for ERCP training. Traditional hands-on ERCP training requires the trainer to be on-site to assist the trainee with ERCP operations. We hypothesized that the trainee can be safely guided by trainer off-site with interactive audio and endoscopic and fluoroscopic view. Technology-enabled health care at a distance has profound scientific potential and accordingly has been met with growing interest. Teleguidance facilitated ERCP cannulation is a strategy to provide expert cannulation guidance to trainee in settings where such expertise is not on-site. Teleguidance not only reduces unnecessary radiation exposure of endoscopist, but also provides remote assistance for trainees to complete training or further improve skills. Given the advantages of the off-site teleguidance, it could be an attractive substitute for on-site hands-on ERCP training.

The primary aim of this study was to evaluate whether off-site assistance (Off group) could achieve a comparable success rate to on-site assistance (On group) regarding the rates of successful selective biliary cannulation during ERCP training.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-90 years old
* With native papilla

Exclusion Criteria:

* History of partial or total gastrectomy (Billroth I/II, Roux-en-Y)
* Type II duodenal stenosis
* Previously failed cannulation
* Chronic pancreatitis with stones in the pancreatic head
* Hemodynamic instability
* Lactating or pregnant women
* Inability to give written informed consent
Factors Affecting Abdominal Compliance During CO2 Insufflation in Laparoscopic Abdominal Surgery

The authors aimed to evaluate factors influencing abdominal compliance in laparoscopic abdominal surgery.

During laparoscopic surgery, pneumoperitoneum is achieved by insufflating carbon dioxide (CO2) gas into the abdominal cavity to create a safe working space. Pneumoperitoneum-induced elevation in intra-abdominal pressure (IAP) can result in various complications. Abdominal compliance (AC), represents the slope of the P-V curve of the abdominal cavity and is a measure of the ease of abdominal dilatation, is important to balance between surgical safety and complications. The aim of this study was to determine the effect of demographic and anatomic variables on AC.

The study included 90 patients who underwent laparoscopic abdominal surgery. Subcutaneous adipose tissue and abdominal muscle thickness were measured ultrasonographically. Mean AC was calculated during insufflation using the formula (ΔV/ΔP). The relationship between demographic and anatomic variables and AC was investigated

Eligibility Criteria:
Inclusion Criteria:

Aged between 18 and 82 years ASA class I-III Elective abdominal surgery with laparoscopic technique

-

Exclusion Criteria:

Aged below 18 and above 82 ASA IV-V
Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease.

A phase 2 clinical trial to evaluate the the efficacy of different benznidazole regimens (300mg/day for 60 days, 150mg/day for 60 days, and 400mg/day for 15 days) for the treatment of chronic Chagas disease in adult patients. The efficacy is assessed through the proportion of patients with negative parasitaemia measured by Polymerase Chain Reaction (PCR) during the first 12 months after starting treatment. The study will be performed in Spain, Brazil, Argentina and Colombia.


Eligibility Criteria:
Inclusion Criteria:

* Over 18 years old.
* Diagnosis of Chagas disease through two different serological tests.
* Positive T. cruzi PCR in peripheral blood.
* Signed informed consent.

Exclusion Criteria:

* Previous treatment with Benznidazole or Nifurtimox.
* Alcohol consumption.
* Acute or chronic health problems that could interfere in the assessment of the efficacy or safety of the drug (acute infections, HIV infection, liver or renal impairment, etc).
* Nitroimidazole hipersensitivity.
* Concomitant or previous treatment with allopurinol or antifungal drugs.
* Pregnancy.
Efficacy of Combination of Midodrine With Propranolol in Preventing First Bleed in Decompensated Cirrhotics With Severe Ascites.

Study population: Decompensated cirrhotics requiring primary prophylaxis with asciteswho are admitted to and attending the OPD at ILBS.

Study Design : A Randomized controlled trial Study period : August 2019 to December 2020 (1.5 Years) Intervention : Treatment naïve patients will be given Propranolol and dose will be titrated every 2ndday to attain a target heart rate of 55.

One group patients will be given maximum tolerated dose of propranolol with initial dosage of 20mg once a day and uptitrating every 2nd day by 20 mg.The patients who bleed will undergo EVL session.

To the other group Midodine will be added to Propranolol.It will be started at 2.5mg TDS and will be uptitrated every 2nd day to a max of 10mg TDS to attain a MAP of atleast 70mm Hg and then uptitate the beta blocker simulataneously to attain the target heart rate. The patients who bleed will undergo EVL session.

Monitoring and assessment :

The patient will be monitored every day. The patient will undergo physical examination, complete blood counts, at baseline, LFT, KFT, at every 2nd day and day 7 from the start of therapy.

Adverse effects : Bradycardia and hypotension due to beta blockers Stopping rule : Severe hyponatraemia (\<125), low mean arterial pressure(\<65) or cardiac output and increasing serum creatinine(\>1.5) identifies more vulnerable patients among those with decompensated cirrhosis, in whom a dose reduction or temporal discontinuation of NSBB treatment will be considered.


Eligibility Criteria:
Inclusion Criteria:

Decompensated Child C cirrhotics with grade II-III requiring primary prophylaxis

Exclusion Criteria:

1. Spontaneous bacterial peritonitis
2. Hepatic Encephalopathy
3. Acute renal failure (S.Cr\>1.5)
4. Hepatorenal syndrome
5. Hypertension
6. Coronary Artery Disease ; H/o arrhythmias, heart block
7. Urinary retention
8. Pheochromocytoma/thyrotoxicosis
9. Coronary Obstructive Pulmonary Disease
10. Hepatocellular Carcinoma
11. Pregnancy
12. Portal vein Thrombosis
Regional Anesthesia in Pediatric Orthopaedic Patients

To identify the benefits from regional anesthesia use as pain management in the pediatric population by delineating the differences in efficacy of continuous nerve blockade versus single-shot techniques after pediatric orthopaedic limb procedures. By doing this, the investigators can determine if specific anesthetic techniques should become a standard of care in pain management for the pediatric population and supersede the need for opioid medication.


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing primary orthopaedic limb surgery
* Outpatient orthopaedic surgeries
* Patients undergoing orthopaedic surgery who would normally receive regional anesthesia

Exclusion Criteria:

* Patients younger than 5 years of ago or older than 18 years of age
* Revision orthopaedic surgeries
* Spinal orthopaedic surgeries
* Orthopaedic surgeries where the standard of care for type of regional anesthesia has been established (continuous regional for ACL reconstruction)
* Patients with the inability to articulate pain scores
* Inpatient orthopaedic surgeries
* Patients undergoing orthopaedic limb surgery with risk of compartment syndrome (i.e. acute supracondylar humerus fractures)
Insulin Resistance Study

The purpose of this study is to evaluate how often patients with hepatitis C infection have abnormalities of sugar and fat utilization. Additionally we would like to find out if these abnormalities of sugar and fat utilization are common in other liver diseases, or related to being overweight.


Eligibility Criteria:
Inclusion Criteria:

* Ability to give written consent
* HCV RNA PCR positive for 6 months
* Normal Hgb, WBC,Neutrophils
* Platelets of \>/= 65,000
* Direct Bili, within 20% ULN
* Albumin \>3
* Serum Creatinine \<20% ULN
* TSH WNL
* AFP \</= 100

Exclusion Criteria:

* Women who are pregnant or breast-feeding
* No Thiazolidinedione, Metformin,unless required for the treatment of type II DM
* Hepatitis C of non-genotype 1,2,3
* Any other cause for liver disease other than chronic hepatitis C
* Hemoglobinopathies
* Evidence of advanced liver disease
* Previous organ transplant
* Severe psychiatric disorder
* Significant cardiovascular dysfunction within the past 12 months
* Poorly controlled diabetes mellitus
* Immunologically mediated disease
* Any medical condition requiring chronic systemic administration of steroids
* Evidence of an active or suspected cancer
* Substance abuse at the time of the study
* Known HIV
* Irritability or unwillingness to provide informed consent
Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

This is an evaluation of Aldafermin (NGM282) in an open-label, single-dose and parallel group study in participants with Impaired Hepatic Function


Eligibility Criteria:
Inclusion Criteria:

1. Males or females, 18 - 75 years of age, inclusive
2. Able to comprehend and willing to sign an informed consent form (ICF)
3. Willing and able to comply with all study requirements
4. BMI 18 - 40 kg/m2, inclusive at Screening
5. Stable medication regimen - no medication initiation or dose change within 7 days or 5 half-lives (whichever is longer) prior to dosing of the study medication.
6. Non-pregnant, non-lactating females. Female subjects of childbearing potential and male subjects with a female sexual partner of childbearing potential must agree to consistent and adequate birth control. One of the following forms of contraception is required:

   1. Condom
   2. Hormone containing contraceptive
   3. Intrauterine device with a failure rate \< 1% per year
   4. Cervical cap or diaphragm with spermicidal agent
   5. Tubal sterilization
   6. Vasectomy in male partner
   7. Sexual abstinence
7. Negative test for drugs of abuse at Screening unless they are currently prescribed
8. Negative human immunodeficiency virus (HIV) antibody screen at Screening

Exclusion Criteria:

1. Any acute disease or condition being treated by medical therapy (prescription or over the counter) known to possibly impact hepatic function
2. History of or recent (\< 6 weeks) treatment for a chronic condition with a medication that is known to have hepatotoxic potential.
3. Any significant physical injury or surgical procedure within 6 weeks of Screening
4. Uncontrolled diabetes (hemoglobin A1c \[HbA1c\] \> 9.5%)
5. Uncontrolled hypertension (systolic blood pressure \[SBP\] \> 180 mmHg on ≥ 3 medications of different classes for blood pressure control)
6. Have received any investigational medication within 30 days or 5 half-lives, whichever is longer, prior to study dosing
7. Subjects should not have donated blood within 60 days of study entry or plasma within 7 days of study entry. Subjects must also refrain from blood donation from clinic admission, throughout the study period, and continuing for at least 30 days following the last dose of study medication.
8. Positive urine drug screen at Screening that is not otherwise explained by a permitted concomitant medication
9. History of alcoholism in the 6 months prior to Screening
10. Inadequate peripheral venous access
Intraoral Scanners as Periodontal and Dental Pathologies Diagnosis Tools

Periodontal diseases and dental pathologies are highly prevalent oral diseases. Thirty-three to fifty percent of adult population presented at least one untreated caries and more than 50% of French population are affected by severe periodontitis. These diseases affect dental organ or periodontal attached system but could have negative impact on general health, quality of life, word and individual well-being. Association between chronic diseases as diabetes, rheumatoid arthritis, cardiovascular diseases, and oral health have been well investigated. Dental and periodontal diagnosis is dependent of various clinical parameters time consuming and dependent operator. It represents a public health challenge. Informatic analysis detecting diseases could be a time gain and a more precise diagnosis tool. Today, any software or algorithm allow automatized detection, clinical qualitative or quantitative indices recording while these informations are present in numeric models

The present study explores the effectiveness of intraoral scanners in the field of dental caries and periodontal diseases diagnosis Patients presenting at least on recession are recruited without randomization. A clinical examination is performed, and a 3D impression of their mouth is obtained by intraoral scanners.

The investigators hypothesized that the 3D intra oral representations could improve oral diagnosis in patients compared to clinical examination in term of time consummation and precision. In a first time, this could be achieved by the comparison of the recession measurement obtained by a clinical measure (Ramfjord, 1959) or obtained by artificial intelligence.

The secondary objectives are :

* To compare clinical and numerical dento-prosthetic diagram
* To compare clinical and numerical plaque control record index (O'Leary et al., 1973)
* To compare clinical and numerical Decayed, Missed and Filled Teeth index (Klein and Palmer, 1940)
* To compare clinical and numerical detection of mucosal lesions

Eligibility Criteria:
Inclusion Criteria:

* adultes
* consulting the Dental Care Service of the university hospital of Reims
* presenting at least one gingival recession
* presenting at least 10 pairs of opposing teeth
* speaking French
* who signed the informed consent form
* affiliated to the French Social Security system

Exclusion Criteria:

Patients presenting :

* pregnancy or breastfeeding
* orthodontic treatments
* patients under legal protection, trusteeship or guardianship
* unable to understand auto-questionnary